Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 121
  1. Oct 09, 2025 · 17:00 · VHI

    VitalHub Announces Novari Health Deployment in the UK

    VitalHub Announces Novari Health Deployment in the UK

    01
  2. Oct 09, 2025 · 12:44 · LOBE

    Lobe Sciences arranges $137,130 (U.S.) debt settlement

    Lobe Sciences arranges $137,130 (U.S.) debt settlement

    02
  3. Oct 09, 2025 · 11:23 · BNXT

    Bionxt completes Track One patent filing for BNT23001

    Bionxt completes Track One patent filing for BNT23001

    03
  4. Oct 09, 2025 · 09:04 · HEM

    Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

    Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

    04
  5. Oct 09, 2025 · 06:50 · LOBE

    Lobe Sciences Improves Balance Sheet

    Lobe Sciences Improves Balance Sheet

    05
  6. Oct 09, 2025 · 03:05 · BNXT

    BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

    BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis

    06
  7. Oct 08, 2025 · 20:25 · VITA

    Vitalist Inc. Commences Trading on the OTCQB Venture Market Under the Ticker "VTLSF"

    Vitalist Inc. Commences Trading on the OTCQB Venture Market Under the Ticker "VTLSF"

    07
  8. Oct 08, 2025 · 19:30 · OTC

    Ocumetics talks 1-month intraocular lens postop results

    Ocumetics talks 1-month intraocular lens postop results

    08
  9. Oct 08, 2025 · 18:27 · NRX

    Nurexone shows vision recovery in glaucoma study

    Nurexone shows vision recovery in glaucoma study

    09
  10. Oct 08, 2025 · 18:14 · PHRM

    Pharmather talks ketamine as Parkinson's treatment

    Pharmather talks ketamine as Parkinson's treatment

    10
  11. Oct 08, 2025 · 17:43 · QNTM

    Quantum Biopharma offers $7M(U.S.) whistleblower reward

    Quantum Biopharma offers $7M(U.S.) whistleblower reward

    11
  12. Oct 08, 2025 · 16:00 · SHRX

    Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025

    Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025

    12
  13. Oct 08, 2025 · 09:25 · OTC

    Ocumetics Reports Encouraging One-Month Postoperative Results

    Ocumetics Reports Encouraging One-Month Postoperative Results

    13
  14. Oct 08, 2025 · 08:30 · NRX

    NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

    NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

    14
← Newer Older →